Skip to main content
Top
Published in: Current HIV/AIDS Reports 2/2013

01-06-2013 | The Global Epidemic (Q Abdool Karim, Section Editor)

Addressing Injecting Drug Use in Asia and Eastern Europe

Authors: Zunyou Wu, Cynthia X. Shi, Roger Detels

Published in: Current HIV/AIDS Reports | Issue 2/2013

Login to get access

Abstract

While the global HIV incidence dropped about 20 % in the past 10 years, HIV incidences among people who inject drugs (PWID) in Asia and Europe continue to increase and to account for high proportions of new HIV infections among PWID globally. Great changes have been observed in this region, such as progressing from rejection to acceptance of harm reduction strategies in Asian countries, but no such change has occurred in Eastern European countries. China has quickly scaled up harm reduction activities nationwide, resulting in the decline of HIV incidence and HIV prevalence among PWID since 2006. However, insufficient scaling up of harm reduction programs in other countries has failed to slow down their HIV epidemics. In Eastern European countries where the spread of HIV among PWID is the most severe, only about 15 % of funding for harm reduction programs are from domestic sources. Strong political and financial commitment from countries in this region is urgently needed to quickly scale up evidence-based harm reduction strategies in order to prevent the HIV epidemic from spreading rapidly from PWID to the heterosexual general population.
Literature
1.
go back to reference UNODC. World drug report 2012. Vienna: UNODC; 2012. UNODC. World drug report 2012. Vienna: UNODC; 2012.
2.
go back to reference Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379:55–70.PubMedCrossRef Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379:55–70.PubMedCrossRef
3.
go back to reference Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systemic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51.PubMedCrossRef Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systemic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51.PubMedCrossRef
4.
go back to reference •• UNAIDS. Global report 2012: UNAIDS report on the global AIDS epidemic. Geneva: UNAIDS; 2012. The annual UNAIDS reports on the HIV/AIDS epidemic provide comprehensive overviews on the global epidemiology of HIV, including testing, treatment, and risk behaviors of the most-at-risk populations. The 2012 report is based on data from 186 reporting countries and summarizes the current progress in reaching the 2015 targets outlined in the 2011 United Nations Political Declaration on HIV and AIDS. •• UNAIDS. Global report 2012: UNAIDS report on the global AIDS epidemic. Geneva: UNAIDS; 2012. The annual UNAIDS reports on the HIV/AIDS epidemic provide comprehensive overviews on the global epidemiology of HIV, including testing, treatment, and risk behaviors of the most-at-risk populations. The 2012 report is based on data from 186 reporting countries and summarizes the current progress in reaching the 2015 targets outlined in the 2011 United Nations Political Declaration on HIV and AIDS.
6.
go back to reference Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–45.PubMedCrossRef Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–45.PubMedCrossRef
7.
go back to reference Strathdee SA, Stockman JK. Estimating the level of HIV prevention coverage, knowledge and protective behavior among injecting drug users: what does the 2008 UNGASS reporting round tell us? Curr HIV/AIDS Rep. 2010;7:99–106.PubMedCrossRef Strathdee SA, Stockman JK. Estimating the level of HIV prevention coverage, knowledge and protective behavior among injecting drug users: what does the 2008 UNGASS reporting round tell us? Curr HIV/AIDS Rep. 2010;7:99–106.PubMedCrossRef
8.
go back to reference Mesquita F, Jacka D, Ricard D, Shaw G, Tieru H, Hu Y, et al. Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: the role of WHO (WPRO). Harm Reduct J. 2008;5:26.PubMedCrossRef Mesquita F, Jacka D, Ricard D, Shaw G, Tieru H, Hu Y, et al. Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: the role of WHO (WPRO). Harm Reduct J. 2008;5:26.PubMedCrossRef
9.
go back to reference Thorne C, Ferencic N, Malyuta R, Mimica J, Niemiec T. Central Asia: hotspot in the worldwide HIV epidemic. Lancet Infect Dis. 2010;10(7):479–88.PubMedCrossRef Thorne C, Ferencic N, Malyuta R, Mimica J, Niemiec T. Central Asia: hotspot in the worldwide HIV epidemic. Lancet Infect Dis. 2010;10(7):479–88.PubMedCrossRef
10.
go back to reference Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Murugavel KG, Iqbal SH, et al. Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India. Am J Epidemiol. 2010;172(11):1259–67.PubMedCrossRef Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Murugavel KG, Iqbal SH, et al. Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India. Am J Epidemiol. 2010;172(11):1259–67.PubMedCrossRef
11.
go back to reference Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–66.PubMedCrossRef Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–66.PubMedCrossRef
13.
go back to reference Volik MV, Karmanova G, Berezina EB, Kresina TF, Sadykova RG, Khalabuda LN, et al. Development of combination HIV prevention programs for people who inject drugs through government and civil society collaboration in the Russian Federation. Adv Prev Med. 2012;2012:874615.PubMed Volik MV, Karmanova G, Berezina EB, Kresina TF, Sadykova RG, Khalabuda LN, et al. Development of combination HIV prevention programs for people who inject drugs through government and civil society collaboration in the Russian Federation. Adv Prev Med. 2012;2012:874615.PubMed
14.
go back to reference Rhodes T, Sarang A, Bobrik A, Bobkov E, Platt L. HIV transmission and HIV prevention associated with injecting drug use in the Russian Federation. Int J Drug Policy. 2004;15(1):1–16.CrossRef Rhodes T, Sarang A, Bobrik A, Bobkov E, Platt L. HIV transmission and HIV prevention associated with injecting drug use in the Russian Federation. Int J Drug Policy. 2004;15(1):1–16.CrossRef
15.
go back to reference Niccolai LM, Verevochkin SV, Toussova OV, White E, Barbour R, Kozlov AP, et al. Estimates of HIV incidence among drug users in St. Petersburg, Russia: continued growth of a rapidly expanding epidemic. Eur J Public Health. 2010;21(5):613–9.PubMedCrossRef Niccolai LM, Verevochkin SV, Toussova OV, White E, Barbour R, Kozlov AP, et al. Estimates of HIV incidence among drug users in St. Petersburg, Russia: continued growth of a rapidly expanding epidemic. Eur J Public Health. 2010;21(5):613–9.PubMedCrossRef
16.
go back to reference Gyarmathy VA, Li N, Tobin KE, Hoffman IF, Sokolov N, Levchenko J, et al. Unprotected sex in heterosexual partnerships of injecting drug users in St Petersburg, Russia. AIDS Behav. 2011;15(1):58–64.PubMedCrossRef Gyarmathy VA, Li N, Tobin KE, Hoffman IF, Sokolov N, Levchenko J, et al. Unprotected sex in heterosexual partnerships of injecting drug users in St Petersburg, Russia. AIDS Behav. 2011;15(1):58–64.PubMedCrossRef
18.
go back to reference Laisaar KT, Avi R, DeHovitz J, Uusküla A. Estonia at the threshold of the fourth decade of the AIDS era in Europe. AIDS Res Hum Retroviruses. 2011;27(8):841–51.PubMedCrossRef Laisaar KT, Avi R, DeHovitz J, Uusküla A. Estonia at the threshold of the fourth decade of the AIDS era in Europe. AIDS Res Hum Retroviruses. 2011;27(8):841–51.PubMedCrossRef
19.
go back to reference Sa S, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268–84.CrossRef Sa S, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268–84.CrossRef
20.
go back to reference Spicer N, Bogdan D, Brugha R, Harmer A, Murzalieva G, Semigina T. 'It's risky to walk in the city with syringes': understanding access to HIV/AIDS services for injecting drug users in the former Soviet Union countries of Ukraine and Kyrgyzstan. Glob Heal. 2011;7:22.CrossRef Spicer N, Bogdan D, Brugha R, Harmer A, Murzalieva G, Semigina T. 'It's risky to walk in the city with syringes': understanding access to HIV/AIDS services for injecting drug users in the former Soviet Union countries of Ukraine and Kyrgyzstan. Glob Heal. 2011;7:22.CrossRef
21.
go back to reference Mimiaga MJ, Safren SA, Dvoryak S, Reisner L, Needle R, Woody G. “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2011;22(11):1305–13.CrossRef Mimiaga MJ, Safren SA, Dvoryak S, Reisner L, Needle R, Woody G. “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2011;22(11):1305–13.CrossRef
22.
go back to reference Ministry of Health of the People’s Republic of China. 2012 China AIDS response progress report. Beijing: Ministry of Health; 2012. Ministry of Health of the People’s Republic of China. 2012 China AIDS response progress report. Beijing: Ministry of Health; 2012.
23.
go back to reference Vuong T, Ali R, Baldwin S, Mills S. Drug policy in Vietnam: a decade of change? Int J Infect Dis. 2012;23(4):319–26. Vuong T, Ali R, Baldwin S, Mills S. Drug policy in Vietnam: a decade of change? Int J Infect Dis. 2012;23(4):319–26.
24.
go back to reference Reid G, Kamarulzaman A, Sran SK. Malaysia and harm reduction: the challenges and responses. Int J Drug Policy. 2007;18(2):136–40.PubMedCrossRef Reid G, Kamarulzaman A, Sran SK. Malaysia and harm reduction: the challenges and responses. Int J Drug Policy. 2007;18(2):136–40.PubMedCrossRef
26.
go back to reference Kissin DM, Mandel MG, Akatova N, Belyakov N, Rakhmanova AG, Voronin EE, et al. Five-year trends in epidemiology and prevention of mother-to-child HIV transmission, St. Petersburg, Russia: results from perinatal HIV surveillance. BMC Infect Dis. 2011;11:292.PubMedCrossRef Kissin DM, Mandel MG, Akatova N, Belyakov N, Rakhmanova AG, Voronin EE, et al. Five-year trends in epidemiology and prevention of mother-to-child HIV transmission, St. Petersburg, Russia: results from perinatal HIV surveillance. BMC Infect Dis. 2011;11:292.PubMedCrossRef
27.
go back to reference Sarang A, Stuikyte R, Bykov R. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy. 2007;18:129–35.PubMedCrossRef Sarang A, Stuikyte R, Bykov R. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy. 2007;18:129–35.PubMedCrossRef
28.
go back to reference Narayanan S, Vicknasingam B, Robson N. The transition to harm reduction: understanding the role of non-governmental organisations in Malaysia. Int J Drug Policy. 2011;22(4):311–7.PubMedCrossRef Narayanan S, Vicknasingam B, Robson N. The transition to harm reduction: understanding the role of non-governmental organisations in Malaysia. Int J Drug Policy. 2011;22(4):311–7.PubMedCrossRef
29.
go back to reference Sullivan LE, Metzger DS, Fudala PJ, Fiellin D. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100(2):150–8.PubMedCrossRef Sullivan LE, Metzger DS, Fudala PJ, Fiellin D. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100(2):150–8.PubMedCrossRef
30.
go back to reference Metzger DS, Zhang Y. Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep. 2010;7(4):220–5.PubMedCrossRef Metzger DS, Zhang Y. Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep. 2010;7(4):220–5.PubMedCrossRef
31.
go back to reference Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28.PubMedCrossRef Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28.PubMedCrossRef
32.
go back to reference • Hammett TM, Des Jarlais DC, Kling R, Kieu BT, McNicholl JM, Wasinrapee P, et al. Controlling HIV Epidemics among injection drug users: eight years of cross-border HIV prevention interventions in Vietnam and China. PLoS One. 2012;7(8):e43141-e. This article reports on one of the longest studies of HIV prevention among PWID in Asia. The research found that a peer-based needle/syringe exchange intervention was strongly correlated with significant reductions in HIV incidence through 96 months.CrossRef • Hammett TM, Des Jarlais DC, Kling R, Kieu BT, McNicholl JM, Wasinrapee P, et al. Controlling HIV Epidemics among injection drug users: eight years of cross-border HIV prevention interventions in Vietnam and China. PLoS One. 2012;7(8):e43141-e. This article reports on one of the longest studies of HIV prevention among PWID in Asia. The research found that a peer-based needle/syringe exchange intervention was strongly correlated with significant reductions in HIV incidence through 96 months.CrossRef
33.
go back to reference •• MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. This article provides a systematic review and meta-analysis of studies that assessed the impact of OST in relation to HIV incidence. OST was associated with a 54 % reduction in risk of HIV infection among PWID.PubMedCrossRef •• MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. This article provides a systematic review and meta-analysis of studies that assessed the impact of OST in relation to HIV incidence. OST was associated with a 54 % reduction in risk of HIV infection among PWID.PubMedCrossRef
34.
go back to reference World Health Organization. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva: World Health Organization; 2004. World Health Organization. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva: World Health Organization; 2004.
35.
go back to reference Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8(3):e1000423-e.CrossRef Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8(3):e1000423-e.CrossRef
36.
go back to reference Lin C, Wu Z, Rou K, Yin W, Shoptaw S, Detels R. Structural-level factors affecting implementation of the methadone maintenance therapy program in China. J Subst Abuse Treat. 2010;38(2):119.PubMedCrossRef Lin C, Wu Z, Rou K, Yin W, Shoptaw S, Detels R. Structural-level factors affecting implementation of the methadone maintenance therapy program in China. J Subst Abuse Treat. 2010;38(2):119.PubMedCrossRef
37.
go back to reference Liu E. Factors influencing client retention in methadone maintenance treatment clinics in China [dissertation]. Los Angeles: University of California, Los Angeles; 2008. Liu E. Factors influencing client retention in methadone maintenance treatment clinics in China [dissertation]. Los Angeles: University of California, Los Angeles; 2008.
38.
go back to reference Hsieh J. Perceived barriers to post-release participation in methadone maintenance treatment: Perspectives of compulsory drug detoxification center detainees in Yunnan, China [dissertation]. Los Angeles: University of California, Los Angeles; 2013. Hsieh J. Perceived barriers to post-release participation in methadone maintenance treatment: Perspectives of compulsory drug detoxification center detainees in Yunnan, China [dissertation]. Los Angeles: University of California, Los Angeles; 2013.
39.
go back to reference • Jolley E, Rhodes T, Platt L, Hope V, Latypov A, Donoghoe M, et al. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open. 2012;2:e001465. This article provides a systematic review of the risk factors associated with HIV prevalence among PWID in Central and Eastern Europe and Central Asia and a discussion of the response to HIV and the policy environments in these regions.PubMedCrossRef • Jolley E, Rhodes T, Platt L, Hope V, Latypov A, Donoghoe M, et al. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open. 2012;2:e001465. This article provides a systematic review of the risk factors associated with HIV prevalence among PWID in Central and Eastern Europe and Central Asia and a discussion of the response to HIV and the policy environments in these regions.PubMedCrossRef
40.
go back to reference Bergenstrom AM, Abdul-Quader AS. Injection drug use, HIV and the current response in selected low-income and middle-income countries. AIDS. 2010;24 Suppl 3:S20–9.PubMedCrossRef Bergenstrom AM, Abdul-Quader AS. Injection drug use, HIV and the current response in selected low-income and middle-income countries. AIDS. 2010;24 Suppl 3:S20–9.PubMedCrossRef
41.
go back to reference Fu JJ, Bazazi AR, Altice FL, Mohamed MN, Kamarulzaman A. Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers. PLoS One. 2012;7(9):e44249.PubMedCrossRef Fu JJ, Bazazi AR, Altice FL, Mohamed MN, Kamarulzaman A. Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers. PLoS One. 2012;7(9):e44249.PubMedCrossRef
42.
go back to reference Vlahov D, Robertson AM, Strathdee S. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis. 2010;50 Suppl 3:S114–21.PubMedCrossRef Vlahov D, Robertson AM, Strathdee S. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis. 2010;50 Suppl 3:S114–21.PubMedCrossRef
43.
go back to reference Sarang A, Rhodes T, Sheon N, Page K. Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse. 2010;45(6):813–64.PubMedCrossRef Sarang A, Rhodes T, Sheon N, Page K. Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse. 2010;45(6):813–64.PubMedCrossRef
44.
go back to reference Chatterjee A, Sharma M. Moving from a project to programmatic response: scaling up harm reduction in Asia. Int J Drug Policy. 2010;21(2):134–6.PubMedCrossRef Chatterjee A, Sharma M. Moving from a project to programmatic response: scaling up harm reduction in Asia. Int J Drug Policy. 2010;21(2):134–6.PubMedCrossRef
45.
go back to reference Zhao Y, Shi CX, McGoogan JM, Rou K, Zhang F, Wu Z. Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bull World Health Organ. 2013;91:93–101. Zhao Y, Shi CX, McGoogan JM, Rou K, Zhang F, Wu Z. Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bull World Health Organ. 2013;91:93–101.
46.
go back to reference Hogg R, Heath K, Yip B, Craib K, O'Shaughnessy M, Schechter M, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–4.PubMedCrossRef Hogg R, Heath K, Yip B, Craib K, O'Shaughnessy M, Schechter M, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–4.PubMedCrossRef
47.
go back to reference Hull MW, Wu Z, Montaner JS. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7(6):579–86.PubMedCrossRef Hull MW, Wu Z, Montaner JS. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7(6):579–86.PubMedCrossRef
48.
go back to reference Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCrossRef Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCrossRef
49.
go back to reference Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008;47(6):825–33.PubMedCrossRef Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008;47(6):825–33.PubMedCrossRef
50.
go back to reference Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–404.PubMedCrossRef Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–404.PubMedCrossRef
51.
go back to reference Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep. 2012;9(4):287–312.PubMedCrossRef Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep. 2012;9(4):287–312.PubMedCrossRef
52.
go back to reference Malta M, Bastos FI, Silva CMFP, Pereira GFM, Lucena FFA, Fonseca MGP, et al. Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men. J Acquir Immune Defic Syndr. 2009;52(5):629–35.PubMedCrossRef Malta M, Bastos FI, Silva CMFP, Pereira GFM, Lucena FFA, Fonseca MGP, et al. Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men. J Acquir Immune Defic Syndr. 2009;52(5):629–35.PubMedCrossRef
53.
go back to reference Bobrova N, Sarang A, Stuikyte R, Lezhentsev K. Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview. Int J Drug Policy. 2007;18:313–8.PubMedCrossRef Bobrova N, Sarang A, Stuikyte R, Lezhentsev K. Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview. Int J Drug Policy. 2007;18:313–8.PubMedCrossRef
54.
go back to reference Dou Z, Chen RY, Xu J, Ma Y, Jiao JH, Durako S, et al. Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. Int J Epidemiol. 2010;39 Suppl 2:ii56–64.PubMedCrossRef Dou Z, Chen RY, Xu J, Ma Y, Jiao JH, Durako S, et al. Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. Int J Epidemiol. 2010;39 Suppl 2:ii56–64.PubMedCrossRef
55.
go back to reference Wen Y, Zhao D, Ma Y, Zhao Y, Lu L, Liu W, et al. Some patient-related factors associated with late access to ART in China' s free ART program. AIDS Care. 2011;23(10):1226–35.PubMedCrossRef Wen Y, Zhao D, Ma Y, Zhao Y, Lu L, Liu W, et al. Some patient-related factors associated with late access to ART in China' s free ART program. AIDS Care. 2011;23(10):1226–35.PubMedCrossRef
56.
go back to reference Zhang F, Haberer J, Wang Y, Zhao Y, Ma Y, Zhao D, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS. 2007;21 Suppl 8:S143–8.PubMedCrossRef Zhang F, Haberer J, Wang Y, Zhao Y, Ma Y, Zhao D, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS. 2007;21 Suppl 8:S143–8.PubMedCrossRef
57.
go back to reference Des Jarlais DC. Learning from HIV epidemics among injecting drug users. Int J Drug Policy. 2010;21(2):97–9.CrossRef Des Jarlais DC. Learning from HIV epidemics among injecting drug users. Int J Drug Policy. 2010;21(2):97–9.CrossRef
58.
go back to reference Smith K, Bartlett N, Wang N. A harm reduction paradox: comparing China's policies on needle and syringe exchange and methadone maintenance. Int J Infect Dis. 2012;23(4):327–32. Smith K, Bartlett N, Wang N. A harm reduction paradox: comparing China's policies on needle and syringe exchange and methadone maintenance. Int J Infect Dis. 2012;23(4):327–32.
59.
go back to reference Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China's response to HIV/AIDS. Lancet. 2007;369(9562):679–90.PubMedCrossRef Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China's response to HIV/AIDS. Lancet. 2007;369(9562):679–90.PubMedCrossRef
60.
go back to reference Wu Z, Rou K, Cui H. The HIV/AIDS epidemic in China: history, current strategies and future challenges. AIDS Educ Prev. 2004;16(3 Suppl A):7–17.PubMedCrossRef Wu Z, Rou K, Cui H. The HIV/AIDS epidemic in China: history, current strategies and future challenges. AIDS Educ Prev. 2004;16(3 Suppl A):7–17.PubMedCrossRef
61.
go back to reference Wu Z, Liu Z, Detels R. HIV-1 infection in commercial plasma donors in China. Lancet. 1995;346:61–2.PubMedCrossRef Wu Z, Liu Z, Detels R. HIV-1 infection in commercial plasma donors in China. Lancet. 1995;346:61–2.PubMedCrossRef
Metadata
Title
Addressing Injecting Drug Use in Asia and Eastern Europe
Authors
Zunyou Wu
Cynthia X. Shi
Roger Detels
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 2/2013
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-013-0153-0

Other articles of this Issue 2/2013

Current HIV/AIDS Reports 2/2013 Go to the issue

The Global Epidemic (Q Abdool Karim, Section Editor)

HIV Testing: Current Practice and Future Directions

The Global Epidemic (Q Abdool Karim, Section Editor)

Antiretroviral Therapy for Prevention Is a Combination Strategy

The Global Epidemic (Q Abdool Karim, Section Editor)

Overview of the Current State of the Epidemic

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.